Aim: To present results for patients with seminoma treated at our University Clinic.
Patients and methods: All men treated for seminoma in 1986-2010 at the Department of Oncology, University Hospital of North Norway were included (n=232). Treatment was standardized from 2000 as the Swedish and Norwegian Testicular Cancer Project (SWENOTECA) published their first standardised seminoma treatment program (SWENOTECA V).
Results: The percentage of patients administered adjuvant radiotherapy (RT) for clinical stage (CS) I decreased gradually from the late 1990s and was abandoned in 2005. Surveillance was the most common management strategy for CS I after 2000. Overall, disease in 1.9% and 11% of patients relapsed after adjuvant RT and surveillance, respectively. There were no relapses after treatment for metastatic disease. Cancer-specific survival was 100%, and overall survival 95% for the total group.
Conclusion: The treatment outcome at our University Clinic is excellent with 100% cancer-specific survival, and is essentially a result of the bi-national SWENOTECA network.
Keywords: Seminoma; carboplatin; chemotherapy; radiotherapy; surveillance; survival.
Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.